Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 7/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.53 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7841588 | 0.81 | POLB (0.54) | NAMPTBLMROCK2HTTLMNA | |
| SCHEMBL13972684 | 0.78 | BLM (0.62) | BLMLMNAMEN1KMT2A | |
| SCHEMBL8822060 | 0.77 | POLB (0.48) | BLMROCK2HTTLMNANPC1 | |
| SCHEMBL16370184 | 0.76 | EPHX2 (0.57) | NAMPTLMNANPC1RAB9AMEN1 | |
| SCHEMBL4357696 | 0.76 | NAMPT (0.59) | NAMPTIMPDH2ROCK2ROCK1HTT | |
| SCHEMBL23316549 | 0.75 | BLM (0.46) | BLM | |
| SCHEMBL18069354 | 0.75 | BLM (0.46) | BLMKMT2A | |
| SCHEMBL16370015 | 0.74 | LMNA (0.57) | NAMPTLMNANPC1RAB9AMEN1 | |
| SCHEMBL16370228 | 0.74 | NAMPT (0.48) | NAMPTLMNAMEN1KMT2A | |
| SCHEMBL19910597 | 0.74 | BLM (0.44) | BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105904-A1 | UREA TYPE CINNAMIDE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105904-A1 | UREA TYPE CINNAMIDE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105904-A1 | UREA TYPE CINNAMIDE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-29 | — | — | US | disclosed |
| CN-101448793-A | Urea type cinnamamide derivative | EISAI R&D MAN CO LTD (JP) | 2009-06-03 | — | — | CN | disclosed |
| EP-2019093-A1 | UREA TYPE CINNAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2009-01-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105904-A1 | UREA TYPE CINNAMIDE DERIVATIVE | SLC14A1, UTS2R, MAN2B1 | NAMPT 3762/4885BLM 4392/4885IMPDH2 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.